Semaglutide for osteoarthritis

Areas affected by osteoarthritis

A recent study published in the New England Journal of Medicine on October 31, 2024, highlights that once-weekly semaglutide significantly reduces body weight and alleviates pain related to knee osteoarthritis in individuals with obesity, compared to a placebo.

Study Overview

Ozempic, a form of semaglutide

The study, led by Henning Bliddal, M.D., from Copenhagen University Hospital at Bispebjerg and Frederiksberg in Denmark, was conducted over 68 weeks at 61 sites across 11 countries. A total of 407 participants with obesity and clinically confirmed moderate knee osteoarthritis characterized by moderate to severe pain were enrolled. Participants were randomly assigned in a 2:1 ratio to receive either once-weekly subcutaneous semaglutide or a placebo, in addition to counseling on physical activity and a reduced-calorie diet.

Key Findings

The study results demonstrated the following:

• Body Weight Reduction: By week 68, participants receiving semaglutide experienced a mean body weight reduction of −13.7%, compared to −3.2% in the placebo group.
• Pain Reduction: The mean change in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain score was −41.7 points for the semaglutide group, compared to −27.5 points for the placebo group.
• Improvement in Physical Function: The 36-Item Short Form Health Survey (SF-36) indicated greater improvement in physical function among the semaglutide group, with a mean increase of 12.0 points compared to 6.5 points in the placebo group.

The incidence of serious adverse events was similar between the two groups, indicating that semaglutide was well-tolerated.

References

• NEJM study - Semaglutide for Osteoarthritis

This article is a medical stub. You can help WikiMD by expanding it!
Most recent articles Ongoing trials	Wikipedia

Ad. Transform your life with W8MD's

GLP-1 weight loss injections special from $29.99

W8MD weight loss doctors team

W8MD Medical Weight Loss, Sleep and Medspa offers physician-supervised medical weight loss programs: NYC medical weight loss Philadelphia medical weight loss

Affordable GLP-1 Weight Loss Shots

Budget GLP-1 injections NYC (insurance & self-pay options) Popular treatments:

• • Semaglutide starting from $29.99/week
  • Tirzepatide starting from $45.00/week

✔ Most insurances accepted for visits ✔ Prior authorization support when eligible

Start your physician weight loss NYC journey today:

📍 NYC: Brooklyn weight loss center 📍 Philadelphia: Philadelphia weight loss center

📞 Call: 718-946-5500 (NYC) | 215-676-2334 (Philadelphia)

Tags: Affordable GLP1 weight loss NYC, Wegovy NYC, Zepbound NYC, Philadelphia medical weight loss